Fort Worth, TX, United States of America

Nasreen Jacobson

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nasreen Jacobson: Innovator in Glaucoma Treatment

Introduction

Nasreen Jacobson is a prominent inventor based in Fort Worth, TX (US). She has made significant contributions to the field of ophthalmology, particularly in the treatment of glaucoma. Her innovative approach focuses on regulating the activity of connective tissue growth factor (CTGF) to lower intraocular pressure and provide neuroprotection.

Latest Patents

Nasreen holds 1 patent for her invention titled "Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies." This patent outlines a method for lowering intraocular pressure by administering a therapeutically effective amount of non-nucleotide or non-protein agents that inhibit the expression and/or signaling of CTGF.

Career Highlights

Nasreen is currently associated with Alcon, Inc., a leading company in eye care products. Her work at Alcon has allowed her to focus on developing innovative solutions for patients suffering from glaucoma and related conditions.

Collaborations

Throughout her career, Nasreen has collaborated with notable colleagues, including Debra L Fleenor and Allan R Shepard. These collaborations have contributed to her success and the advancement of her research.

Conclusion

Nasreen Jacobson's innovative work in glaucoma treatment exemplifies the impact of research and invention in improving patient care. Her dedication to advancing ophthalmic therapies continues to inspire others in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…